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Abstract 
Review on S100A4, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: 18A2, 42A, CAPL, FSP1, MTS1, 
P9KA, PEL98 
HGNC (Hugo): S100A4 
Location: 1q21.3 
Local order 
The 1q21 locus harbours the epidermal 
differentiation complex (EDC) encompassing a 
2.05 Mbp of human genomic DNA. The S100 
family genes except the S100beta are arranged in 
the following order: 1 cen-S100A10-S100A11-
THH (trychohyalin)-FLG (filaggrin)-IVL 
(involucrin)-LOR (loricrin)-S100A9-S100A12-
S100A8-S100A7A-S100A7P1-S100A7L2-
S100A7P2-S100A7-S100A6-S100A5-S100A4-
S100A3-S100A2-S100A16-S100A14-S100A13-
S100A1-1qtel. S100beta is located on 21q22.3 
(Schäfer et al., 1995; Marenholz et al., 1996; 
Mischke et al., 1996; GeneLoc version 2.41: 
pseudogenes S100A7P1: HGNC 21654, 
S100A7P2: HGNC 21656). S100A11 pseudogenes 
have been listed (Pseudogenes.org); they are not 
shown here. 
The 18A2 cDNA/mRNA (S100A4) was cloned and  
its structure, translation product and tissue 
distribution were described by Jackson-Grusby and 
colleagues. The sequence of 18A2 was similar to 
that of the 2A9 clone described by Calabretta and 
collegues. 
DNA/RNA 
Note 
Starts 153516089 bp from pter; ends 153522612 bp 
from pter; 6524 bases; orientation minus strand. 
Homo sapiens chromosome 1, GRCh37 primary 
reference assembly. 
NCBI reference sequence: NC_000001.10, 
NT_004487.19. 
Description 
The human S100A4 gene has four exons. Exon 1 is 
non-coding and exons 2 and 3 are coding exons. 
Exon 2 with the start codon and encodes N-terminal 
EF hand and exon 3 encodes the C-terminal EF-
hand. The fourth non-coding exon occurs in the 5'-
UTR. 
Transcription 
Two variant RNA transcripts from Source Search. 
The NM_019554 is a longer transcript. 
NM_002961 possesses alternate 5'-UTR; both 
encode the same protein isoform. 
NCBI reference sequence NM_019554 ver 01954.2 
564 bp mRNA; NM 002961 ver 002961.2; 512 bp 
mRNA. 
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Figure 1. A. Chromosome 1 ideogram showing the location of S100A4 based on National Library of Medicine Handbook. B. The 
position of S100A4 is based on Entrez Gene ID 6275 (not drawn to scale). 
 
Splice variants have been reported of S100A4. In 
human osteosarcoma, alternative splicing within the 
5'-untranslated region (UTR) generates the two 
variants. Both variants, hu-mts1 and hu-mts1 (var), 
contain one open reading frame, differ slightly in 
translational capacity; possess similar stability. The 
hu-mts1 and hu-mts1 (var) splice variants with 
exons 1, 2, 3, and 4 and another with exons 1, 3 and 
4, may be differentially expressed. The hu-mts1 
(var) is expressed in the colon but not in the liver; it 
was not found in leukocytes, neutrophils, 
macrophages and lymphocytes. The hu-mts1 
variant predominated in human breast carcinoma 
(SK-BR-3) and lung carcinoma (A549) is 
predominant (Ambartsumian et al., 1995). The 
differential association of the variants has been 
described in gastric cancers, which seems to relate 
to disease state possibly relates to progression; 
however the expression status of the variants in the 
lymph node metastases is not known. A splice 
transcript with loss of non-coding exon 1a/1b, but 
exons 2 and 3 present has been described in 
infiltrating carcinoma of the breast by Albertazzi et  
al.. One would note nonetheless that Alternative 
Splicing and Transcript Diversity (ASTD) have 
listed 12 variant transcripts. 
Regulation of transcription 
Binding sites for several transcription factors have 
been identified in the promoter of S100A4. 
SABiosciences ChIP-qPCR Assay database lists 19 
p53 binding sites. 
Multiple NFAT (nuclear factor of activated T cells) 
transcription factor consensus binding sites; NF-
kappaB related binding site (Tulchinsky et al., 
1997). Much evidence is also available regarding 
activation of NF-kappaB by S100A4. S100A4 can 
activate NF-kappaB via the classical pathway 
mediated by MEKK/IKKβ; S100A6 and S100P also 
are capable of exerting pro-metastatic effects again 
by activating the NF-kappaB pathway. 
Experimentally induced expression of S100A4 is 
inhibited by NF-kappaB inhibitors. Aside from 
these, several other regulatory pathways may be 
identified, e.g. the Wnt/β-catenin/TCF, HIF/HER 
among others, as evidenced by the established 
phenotypic expression induced by the gene. 
 
Figure 2. Based on USCS GRCh37/hg19 Feb. 2009. Not drawn to scale. 
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Figure 3. Sequence. 
 
 
S100A4 has been postulated to signal via RAGE 
(receptor for advanced glycation end products) 
which is known to activate NF-kappaB. 
A composite enhancer consisting of 6 cis-elements 
has been identified in the first intron of murine 
S100A4. This interacts with Sp1 and AP-1 family 
members and CBF (core binding factor alpha) and 
KRC (zinc finger transcription factor kappa 
recognition component) transcription factors. 
Pseudogene 
None reported. 
Protein 
Description 
Human S100A4 (also mouse and rat S100A4) 
contains 101 aminoacid residues and is approx 12 
kDa in size. In common with most S100 family 
members, S100A4 is an antiparallel homodimer 
stabilised by noncovalent interactions between two 
helices from each subunit forming an X-type four-
helix bundle. Each subunit has two calcium-binding 
EF-hands linked by the intermediate hinge region 
and a distinctive C-terminal extension. A pseudo-
EF hand formed by helices 1 and 2 and the pseudo-
EF-hand and a canonical EF-hand that are brought 
into proximity by a small two-stranded antiparallel 
beta-sheet. The hinge region and the C-terminal 
loop of S100 proteins are involved in target protein 
binding. Calcium binding produces a 
conformational change, which leads to the exposure 
of hydrophobic pocket of residues in helices 3 and 
5, the hinge region and the C-terminal loop. This 
conformational change is required for target protein 
binding. S100A4 might be post-translationally 
modified. Charged variants conceivably resulting 
from post-translational changes have been 
described in one report, but no confirmation of 
these findings has been forthcoming. However, 
calculations from the predicted isoelectric point of 
S100A4 and separation of the charged variants 
from the major spot would suggest that two variants 
may have displayed 17.4 and 26.1% and a third 
variant with a possible highly extended form and 
nearly 2.6-fold increase in net negative charge. 
Alterations in net molecular charge of this 
magnitude and charge distribution can alter protein  
 
 
configuration. 
NCBI sequence: NM_002961; NP_002952; 
NM_019554; NP_062427; UniProtKB/Swiss-Prot: 
P26447. 
Features 
EF-hand domains: 
EF hand 1: length 36; position 12-47, 
EF hand 2: length 36; position 50-84. 
Target protein interaction domains: in the active 
state S100A4 interacts with many target proteins 
e.g. p53 family proteins, HDM2, Annexin II, F-
actin, tropomyosin, and heavy chain of non-muscle 
myosin IIA, among others. In a closed 
conformational state S100A4 is inactive, but the 
protein assumes an open conformation upon 
calcium binding. In the altered configuration 
S100A4 can interact with target proteins. These 
target proteins interact with specific binding 
domains of S100A4, which are accessible upon 
conformational change of the apoprotein upon Ca2+ 
binding. The Rudland/Barraclough group has 
shown that specific mutations that inhibit self-
association of S100A4 markedly reduce its 
metastasis promoting effects. The mutations reduce 
self-association and reduce the affinity of S100A4 
to two target proteins viz. p53 and non-muscle 
myosin heavy chain isoform A. The interaction 
between S100A4 and target proteins can possibly 
also be disrupted by the packaging of S100A4 in 
such a way as to sequester S100A4 dimers. 
Inhibition of S100A4 polymerisation by 
suppressing TG2 (tissue transglutaminase 2) 
function has resulted in the inhibition of cell 
migration in vitro. This is inspired by the fact that 
TG2 is a cross-linking protein. Treatment of cells in 
vitro with EGF seems to up regulate the expression 
of EGFR and TG2 accompanied by enhanced cell 
migration. S100A4 over expressing tumours not 
infrequently tend to be EGFR postive; so tissue 
transglutaminase could be promoting EGFR 
dimerisation and facilitate EGF/EGFR signalling. 
Expression 
S100A4 is distributed ubiquitously in normal 
tissues (Mazzucchelli, 2002). 
For expression profile: Human Protein Atlas 
(HPA): CAB002618 and Human Protein Reference 
Database HPRD. 
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Figure 4. S100A4 undergoes a calcium-dependent conformational rearrangement that exposes the protein target binding cleft. 
Ribbon diagrams showing the NMR solution structure of apo-S100A4 (PDB code 1M31) and the X-ray structure of calcium-
bound S100A4 (PDB code 2Q91). Following the addition of calcium (yellow spheres), helix 3 (green helix in dark blue monomer) 
moves to expose the target bind cleft. This conformational rearrangement is required for S100A4 binding to protein targets. The 
author is grateful to Anne R. Bresnick, Ph.D., Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, 
for providing this illustration and the brief legend. 
 
S100A4 occurs in many forms of human cancer, 
e.g. breast, colorectal, liver, lung, head and neck, 
ovarian, endometrial, pancreatic, renal, testicular, 
and prostate cancers, and melanoma; also in many 
cell lines of myeloid, lymphoid, lung and brain 
origin and cell lines derived from many forms of 
leukaemias. The expression of the gene is regulated 
by methylation. Over expression correlates with 
hypomethylation and the frequency of 
hypomethylation relates to tumour progression, e.g. 
in ovarian cancers. There is no implication at 
present that the degree of methylation is related to 
expression. S100A4 has been implicated in other 
human diseases, e.g. Crohn's disease and 
rheumatoid arthritis. 
Localisation 
S100A4 occurs extracellulary and also in 
cytoplasmic and nuclear location. Differential 
distribution has been reported between stromal 
components of primary and metastatic tumour. 
Patterns of distribution could vary between tissues 
and between species. No firm functional link has 
been made with the site/s of localisation. 
Intracellular distribution is an important factor in 
determining genetic activity. 
It may be noted here that S100A4 is often 
expressed in component inflammatory cells of 
tumour stroma. It has been postulated that 
interactions between the stroma and tumour cells 
lead to the expression of the protein and modulate 
its function in either or both. However, both the 
postulate and its potential influence in tumour 
progression are yet to be established. 
The pattern of intracellular distribution of many 
genetic determinants has been found to be highly 
relevant to invasion and metastasis. Nuclear 
location of S100A4 was shown some while ago to 
relate to aggressive tumour behaviour and poor 
prognosis. Translocation to the nucleus has been 
associated with EMT induced by TGF-β/Smad 
signalling. IL-induced translocation seems to 
require sumoylation of specific lysine residues and 
in this way conceivably regulating target gene 
expression. Expression patterns need to be explored 
in more than one tumour system. This might be 
crucial in the development of strategies of treatment 
targeting S100A4, especially with the postulated 
link of S100A4 expression with chemoresistance. 
Function 
S100A4 protein promotes metastasis, functions as a 
counter point to metastasis suppressor nm23, and is 
implicated in the regulation of the cell cycle, cell 
proliferation, motility, invasion, tubulin 
polymerisation, and angiogenesis. S100A4 might 
suppress expression of other suppressor genes e.g. 
PRDM2 and VASH1. PRDM2 (PR domain 
containing 2, with ZNF domain) is a tumour 
suppressor gene encoding a zinc finger protein. 
VASH1 (vasohibin 1) inhibits cell migration, 
proliferation and tumour growth and angiogenesis. 
S100A4 promotes metastatic spread of cancer as 
demonstrated by gene transfer studies. Its 
expression has shown clear correlation with tumour 
spread to lymph nodes and with prognosis. 
Cell cycle, cell proliferation, tumour growth and 
apoptosis. 
S100A4 binds to and forms complexes with p53 to 
regulate cell cycle progression. P53 has been 
confirmed as a target of S100A4, which stabilises 
p53. There is conclusive evidence that S100A4 
binds to C-terminal regulatory region of p53. 
S100A4 and certain other members of the S100 
family bind to TAD transactivation domain 
(residues 1-57) of p53.  
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Figure 5. 
 
They may also affect p53 function by binding to the 
tetramerization domain of p53 (residues 325-355) 
and interfering with intracellular translocation and 
subcellular localisation. 
This interaction is suggested to be linked with p53 
function. Nineteen p53 binding sites have been 
identified in the promoter of S100A4 
(SABiosciences ChIP-qPCR Assay). S100A4 also 
influences waf1 ID: 139> and mdm2, a regulator of 
p53 function and the apoptosis family bax gene. It 
binds to N-terminal domain of mdm2. Signalling 
pathways include P53-Rb/stathmin/p53 down 
stream effectors, e.g. p21waf, p16 etc. P53/stathmin 
signalling modulates microtubule dynamics and cell 
division. Furthermore, p53 and down stream target 
apoptosis family genes such as BNIP3, caspases; 
calpain/Fas (?) are postulated as important 
pathways in S100A4 signalling. Knockdown of 
S100A4 has been reported to lead to apoptosis. The 
transcription factor NF-kappaB which involved in 
anti-apoptosis has been implicated in S100A4 
signalling. 
S100A4 proliferative signalling seems to involve 
epidermal growth factor receptors (EGFR). EGFR 
expression correlates with S100A4 expression. 
Interactive signalling with HER2 might be 
postulated with the finding that S100A4 stimulates 
EGFR/HER2 receptor signalling and on the 
identification in human S100A4 promoter of an 
HER2 response element 1099-1487 bp up stream of 
the transcription start site. The interaction of 
S100A4 with the TGF-beta system via Smad has 
also been reported. S100A4 seems able to bind to 
the N-ter region of Smad3. TGF-beta is an 
important activator of epithelial mesenchymal 
transition leading to acquisition of invasive ability. 
The interaction between S100A4 and Smad thus 
falls in place with the metastasis-promoting 
function of the former. Some of these pathways are 
pictorially represented above (figure 5). S100A4 
activates EMT via up regulation of Snail, a negative 
regulator of E-cadherin. The TGF-β family receptor 
Activin involvement has been implicated. 
Invasion, motility, and intercellular adhesion. 
One of the targets of S100A4 involved in cell 
motility is myosin filaments. Myosin II consists of 
two heavy chains (MHC) with globular domains 
which interact with F-actin. The tail domains of 
heavy chains form a coiled-coil tail that participates 
in the assembly of myosin filaments. Wrapped 
round the neck region of each heavy chain are the 
essential and the regulatory light chains. 
Phosphorylation of the regulatory light chain and 
also of MHC plays an important part in the 
assesmbly of myosin II monomers into filaments. 
S100A4 inhibits CK2-mediated phosphorylation of 
MHC, inhibits the assembly of myosin monomers 
into filaments. The affinity of S100A4 for the 
myosin-IIA can be reduced by CK2-mediated 
phosphorylation. S100A4 destabilises MHCIIA 
filaments phosphorylated by PKC and inhibits the 
assembly of monomers. PKC and CK2 can 
phosphorylate distinct serine residues but yet be 
additive in their effect. The outcome is that S100A4 
promotes dissociation of the filaments and prevents 
self assembly of monomers resulting in enhanced 
migration. Thus S100A4 seems to provide a 
mechanistic link between the actomyosin 
cytoskeletal and migration. 
Signalling systems include modulation of 
cytoskeletal dynamics; cadherin/catenin complex 
cytoskeletal linkage and significantly a TCF, a 
component of the canonical Wnt signalling system, 
binding site has been identified in the S100A4 
promoter and S100A4 directly binds heterodimeric 
beta-catenin/TCF complexes; CD44/cytoskeletal 
linkage; ECM associated proteolytic enzyme 
system/ECM remodelling, affects tubulin 
polymerisation. S100A4 and tumour suppressor 
nm23 exert opposite effects on tubulin dynamics. 
Two C-terminal lysine residues are required for 
enhanced motility and invasion and interaction with  
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target proteins. The connective tissue growth factor 
(CTGF) has been reported to up regulate S100A4 
expression and inhibition of S100A4 blocks CTGF-
induced cell motility. 
S100A4 seems to function via the MMP/TIMP 
system in promoting invasion as well as induction 
of angiogenesis. S100A4 is over expressed in 
invasive glioma cell lines together with down 
regulation of TIMP-2, indicating a close linkup of 
S100A4 with the MMP system in the promotion of 
invasion. 
Angiogenesis signalling occurs via activation of 
MMP/TIMP; activation of angiogenic factors 
VEGF/endothelial cell proliferation; MetAP2/p53-
mediated inhibition of endothelial cell proliferation. 
S100A4 stimulates angiogenic signalling in breast 
cancer. An indirect link is suggested by the 
inhibition of S100A4 by Interferon-gamma which 
might inhibit angiogenesis by down regulating 
VEGF expression. Hypoxia is a major regulator of 
angiogenesis. HIF-1α (hypoxia-inducible factor-1α) 
is a transcription regulator in hypoxia. It can 
activate VEGF to induce angiogenesis and TGF-α 
and promotes cell survival. Exposure to hypoxia 
has been correlated with reduced methylation of the 
hypoxia response element in S100A4's promoter 
region and enhanced HIF binding to the promoter 
and increased transcription of the gene together 
with increased cell proliferation and invasion. 
Given that HIF also promotes VEGF expression 
one can see a potential two pronged approach to 
control tumour growth with HIF inhibition. Some 
clinical studies are underway to study the effects of 
Sorafenib-mediated inhibition of HIF-1α and 
VEGF. In laboratory studies Sorafenib has been 
found to reduce tumour growth and tumour 
associated microvessel density. 
Osteopontin was identified as a metastasis-
associated protein some time ago. Many strands of 
evidence suggest that osteopontin is an 
intermediary in S100A4 signalling pathway. In 
breast cancer expression of osteopontin in the 
background of S100A4 has generally correlated 
with poor patient survival. 
Osteopontin is associated with several activated 
NF-kappaB pathways. S100A4 induces the 
expression and secretion of osteopontin in some 
osteosarcoma cell lines in an NF-kappaB-dependent 
fashion. Inhibition of osteopontin inhibits tumour 
development and angiogenesis; inhibition of both 
might result in synergistic suppression of tumour 
progression. 
Shown below are the potential pathways of S100A4 
signalling in cell motility/invasion and 
angiogenesis, emphasising the possibility that 
S100A4 seems able to influence many significant 
systems leading to angiogenesis. 
Homology 
Sequence homology to protein from Pan 
troglodytes (Chimpanzee) (Gene ID: 457320; 
Protein NCBI RefSeq: XP_001138744.1). 
Bos taurus (Bovine) (Gene ID: 282343). 
Canis lupus familiaris (Gene ID: 403787; NCBI 
reference sequence: NP_001003161.1; protein: 
NP_777020.1). 
Sequence homology 93% to murine S100A4 
(Entrez Gene ID 20198; NP_035441). 
Sequence homology 91% to rat protein (Entrez 
Gene ID 24615; NP_036750). 
 
Figure 6. 
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Mutations 
Note 
Many SNPs have been identified; 7 shown in NCBI 
and 26 in Applied Biosystems data source. The 
NCBI Entrez SNP database lists 19 submissions.  
Chromosomal rearrangements 
The locus 1q21 is a hotspot for chromosomal 
rearrangements, microdeletions and duplications; 
significance uncertain and there are no clear 
implications for metastasis. No translocations 
leading to hybrid S100A4 have been recorded. 
There are 11 common and 1 rare fragile sites on 
chromosome 1. The common FRA1F occurs in 
1q21. Chromosome 1 is prone to sister chromatid 
recombination (SCR) and >70% SCRs occur at the 
fragile sites or in the same band as the fragile sites, 
but no link with S100A4 established. 
Germinal 
None reported. 
Somatic 
No simple mutations, gene fusions, or structural 
variants detected in breast and colorectal 
carcinomas and in gliomas (Cosmic: Catalogue Of 
Somatic Mutations In Cancer, Welcome Trust 
Sanger Institute). 
No mutations have been found coding regions in 
human, canine and feline S100A4. Mutating 
phenylalanine 72 to alanine reduces functional 
effectiveness. Toombak (tobacco rich in tobacco-
specific nitrosamine) dipping (placing between the 
lower lip and gums) has been indirectly linked with 
S100A4 mutations in oral squamous cell 
carcinoma, but mutations have been described also 
in non-dippers. The carcinoma from dippers had 4 
mutations (one transition, 3 transversions) and non-
snuff-dippers showed 3 mutations each (one 
transition, 2 transversions). The suggestion is that 
S100A4 mutations could be complementing the 
effects of more frequent mutations of p53 and 
p21waf1. 
Implicated in 
General notes on association with 
human cancer 
Note 
S100A4 has been implicated in the progression and 
prognosis of several forms of human cancer, e.g. 
breast, colorectal, gastric, pancreatic and bladder 
cancer, SCLC and oesophageal squamous cell 
carcinoma, among others. Poor prognosis 
associated with high S100A4 expression is 
accompanied by clear signs of disease progression, 
e.g. high histological and clinical grades and 
involvement of lymph nodes. 
Also indicative of poor prognosis is high S100A4 
expression coupled with reduced E-cadherin 
expression in pancreatic, oral squamous cell 
carcinoma and in melanoma. S100A4 expression is 
inversely related with expression of metastasis 
suppressor nm23 and with prognosis of breast 
cancer. 
Cytogenetics 
No cytogenetic data are available. 
Abnormal protein 
No fusion proteins or hybrid genes involving 
S100A4 are known. 
Breast cancer 
Note 
Both tumour and serum levels are reportedly 
enhanced in breast cancer patients. S100A4 
expression is inversely related to that of the 
metastasis suppressor nm23 in breast cancers. 
Tumour levels might correlate with proliferative 
state and shown to be linked with p53 dysfunction. 
S100A4 proliferative signalling seems to involve 
epidermal growth factor receptors (EGFR). Breast 
cancers that are high S100A4s expressers tend to be 
oestrogen (ER)/progesterone receptor (PR) 
negative.  
Given that ER/PR expression is inversely related to 
the expression of epidermal growth factor receptors, 
ER/PR status together with S100A4/nm23 
expression status could provide significant leads to 
the prediction of prognosis. S100A4 signalling 
could interact with HER2 function; this is 
suggested by the finding that S100A4 stimulates 
EGFR/HER2.  
Up regulated expression was associated with 
increased tumour angiogenesis and this would be 
expected to contribute to the invasive spread of 
breast cancer.  
Of some interest is the suggestion that 
phosphosulindac might target and induce apoptosis 
of breast cancer stem cells. 
Prognosis 
S100A4 may be regarded as an independent 
predictor of prognosis. 
Colorectal cancer 
Note 
Primary cancers show enhanced S100A4 
expression and associated with metastatic disease in 
the lymph nodes.  
Up regulation of its expression has been correlated 
with enhanced invasion and nodal dissemination. 
Nuclear expression has been reported to be a 
prognostic indicator.  
As in the case of breast cancer there are indications 
that S100A4 might interact with and abrogate p53 
function. The implied association with aggressive  
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disease is underscored by the emergence of 
correlated expression of S100A4 with the 
extracellular matrix metalloproteinase inducer 
CD147/Basigin/EMMPRIN but a causal link is yet 
to be established. One should note in this context 
that S100A9 can also bind CD147.  
Efforts are being made to inhibit Wnt/β-catenin 
mediated targeting of S100A4 using sulindac. 
Bladder cancer 
Note 
Higher expression S100A4 has been observed and 
this might be associated with muscle invasion. 
Prognosis 
High expression has been related to decreased 
survival. 
Oesophageal squamous cell 
carcinoma 
Note 
S100A4 expression levels negatively corresponded 
with E-cadherin expression in ESCCs patients with 
metastatic disease. In vitro studies of migration of 
cells with experimentally enhanced S100A4 
expression have lent support to the perceived 
relationship. Transfection of gall bladder carcinoma 
cell lines E-cadherin has led to the suppression of 
S100A4. 
Ovarian cancer 
Note 
The expression of nuclear S100A4 expression is 
associated with more aggressive disease in primary 
carcinoma where the level of expression has been 
reported to be higher in solid tumours than in 
effusions. 
Lung cancer 
Note 
Higher expression of S100A4 has been encountered 
in squamous cell but not adenocarcinoma of the 
lung. 
Prognosis 
A large study of the expression levels has revealed 
S100A4 to be significantly predictive of survival in 
squamous cell but not adenocarcinoma of the lung. 
S100A4 was significantly associated with patients' 
poor prognosis in lung squamous cell carcinoma 
but not lung adenocarcinoma. 
Pancreatic cancer 
Note 
S100A4 up regulation might be accompanied by 
reduced E-cadherin expression. This inverse 
relationship has also been encountered in melanoma 
and oral squamous cell carcinoma cell lines. This 
might generate an additive effect on tumour 
aggression.  
Perineural invasion has been associated with 
enhanced S100A4 expression. Worthy of note is 
that perineural invasion is a feature linked with 
tumour spread and poor prognosis and its 
correlation with S100A4 might have implications 
for disease management. 
Prognosis 
Some preliminary evidence is available indicating 
that S100A4 expression levels relate to shorter 
overall survival of patients with pancreatic cancer. 
Gastric cancer 
Note 
Higher expression of S100A4 has been noted in 
gastric cancer and correlated with the presence of 
the tumour in lymph node and the occurrence of 
distant metastases, and with poor prognosis. 
Consistent with the situation in certain other forms 
of cancer, in gastric cancer S100A4 levels inversely 
relate to E-cadherin expression. Indeed, down 
regulation of E-cadherin has been found to occur in 
parallel with hypomethylation of S100A4. 
Melanoma 
Note 
A marked inverse relationship has been described 
between S100A4 and E-cadherin in these tumours. 
Gliomas 
Note 
S100A4 is over expressed in invasive glioma cell 
lines together with down regulation of TIMP-2, 
indicating a close linkup of S100A4 with the MMP 
system in the promotion of invasion. This ability to 
induce angiogenesis and metastatic dissemination 
could be complemented and indeed augmented by 
its postulated ability to enhance endothelial 
permeability. Occludin is a transmembrane tight-
junction protein essential for maintaining integrity 
of both epithelia and endothelia. S100A4 is said to 
reduce occludin expression and could compromise 
in this way the integrity of the vascular 
endothelium. This might enhance endothelial 
permeability. Indeed the ability of tumours to form 
metastatic deposits in the brain has been attrributed 
to possible dysfunction of the blood brain barrier. If 
future work provides substantive evidence for this, 
this might have potential implication for the 
management of metastatic disease. But then it ought 
to be recognised here that gliomas do not normally 
metastasise to extracranial sites. Glioma cell lines 
do over express S100A4, but there is little 
information concerning the tumours. S100A8 and 
S100A9 have been implicated to impede diapedesis 
with up regulated expression of the adhesion 
proteins ICAM-1 and VCAM-1. S100A4 and A9 
can form heterodimers in vivo and the heterodimers 
carry features that resemble S100A9 homodimers in  
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respect of the ability to bind pro-inflammatory 
receptors. It is not known if S100A4 and A9 
heterodimers and A9 homodimers differ with 
regard to effects on endothelial permeability. 
Crohn's disease (a form of irritable 
bowel disease) 
Note 
S100A4 expression is increased in structure 
fibroblasts of fibrostenosing Crohn's disease 
promoting intestinal fibroblast migration. 
Rheumatoid arthritis 
Note 
Increase S100A4 mRNA found in proliferating 
synovial fibroblasts. Also protein expression up 
regulated in rheumatoid arthritis synovial tissues 
and linked with joint invasion. IL-7 and S100A4 
occurs in cartilage osteoarthritis and can lead to 
increased MMP-13 production by chondrocytes. 
The JAK/STAT/RAGE signalling has been 
implicated here. 
Psoriasis 
Note 
Many S100 proteins are found in the dermis. 
S100A4 is up regulated in the dermis and colossal 
release of the protein has been reported. Enhanced 
stabilisation of p53 near cells expressing S100A4 
has been noticed. It appears to affect cell 
proliferation and induce angiogenesis. Suppression 
of S100A4 using antibodies seems to suppress 
vascularisation of psoriatic skin xenografts, 
together with diminution of both number and size 
of blood vessels. There are no suggestions of co-
operative or interactive function of S100A4 with 
S100A7 (Psoriasin). 
Cardio-vascular, nervous and 
pulmonary systems 
Note 
The focus in this review is on the role of S100A4 in 
the disease process. Indeed, S100A4 is expressed in 
normal as well as in pathological conditions, 
subserves several physiological functions such as 
regulating macrophage motility, and participates in 
fibrosis and tissue remodeling in several diseased 
and damaged states, e.g. fibrosis of the kidney and 
loss of renal function, cardiac fibrosis, tissue repair 
and regeneration and wound healing; central 
nervous system injury, and pulmonary vascular 
disease.  
S100A4 may be involved in disorders of these 
systems, but data currently available are somewhat 
fragmentary. Both S100A4 mRNA and protein are 
said to be up regulated in the hypertrophic hearts. 
Up regulation is associated with hypertrophy 
induced by aortic stenosis or myocardial infarction. 
In vitro, recombinant S100A4 protein increases the 
number of viable cardiac myocytes. The 
ERK1/ERK2 signalling system has been found to 
be activated in these processes. 
Two putative neurotropic motifs have been 
identified in S100A4 and neuroprotective function 
has been attributed to the protein.  
S100A4 might be associated with PAH (pulmonary 
arterial hypertension) and putatively linked with 
17β-oestradiol modulated S100A4/RAGE 
signalling. A clinical trial is underway at present to 
study S100A4 as a marker in PAH treatment 
(NCT01305252). 
Breakpoints 
Note 
A 1q21 breakpoint was described some time ago in 
renal cell carcinoma (RCC)-associated 
(X;1)(p11;q21) translocation. This has been 
mapped to the S100 gene cluster, but its link with 
S100A4 is uncertain. No translocations involving 
S100A4 have been recorded. No fusion proteins or 
hybrid genes involving S100A4 are known. 
There are 11 common and 1 rare fragile sites on 
chromosome 1. The common FRA1F occurs in 
1q21. Chromosome 1 is prone to sister chromatid 
recombination (SCR) and >70% SCRs occur at the 
fragile sites or in the same band as the fragile sites, 
but no link with S100A4 has been established. 
To be noted 
Note 
S100A4 expression has been linked with 
chemoresistance, but the mechanisms involved 
remain to be elucidated. Whether this occurs via 
engagement of RAGE by S100A4 and activation of 
RAGE signalling leading up to chemoresistance is 
an avenue yet to be explored.  
S100A4 activates interacting and multi-functional 
signalling systems, including EMT signalling 
systems such as Wnt/β-catenin, NF-kappaB, and E-
cadherin among others, highly relevant in the 
context of cancer. Mediation of its function by 
osteopontin and potential function of S100 family 
proteins to act as RAGE ligands are imporatnt 
considerations. These would make S100A4 an 
eminently valuable chemotherapeutic target. Some 
downstream effectors of the S100A4 pathways 
might also lend themselves as targets of interest. 
The diversity of biological effects flowing from the 
inappropriate expression of S100A4 and 
interactions of S100A4 signalling with several 
systems which modulate biological response would 
merit investigations into suppressing S100A4 
expression as a possible therapeutic approach. 
S100A4 function is allied with growth factor and 
steroid hormone receptors and osteopontin which is 
itself subject to regulation by Wnt, NF-kappaB 
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among others, so here is ample provision of options 
available for therapeutic studies. Also the perceived 
link up between EMT and S100A4 expression 
affords fresh avenues of approach. 
The antihelminth drug Niclosamide which targets 
the Wnt/β-catenin pathway can suppress S100A4 
expression with parallel inhibition of cell 
proliferation, migration, promotion of apoptosis, 
and metastatic spread in vitro and xenograft tumour 
models.  
Xanthohumol is a prenylflavonoid antioxidant, 
derived from the female flowers of the hops plant 
(Humulus lupulus). It was identified to possess 
anticancer properties some while ago. Recent work 
has shown its ability to suppress cell proliferation, 
invasion and tumour progression. The flavonoid has 
been found to inhibit proliferation and invasion in 
many breast cancer cell lines, including the triple 
negative breast cancers MDA-MB-231 cells. It 
induces apoptosis and might be functioning by 
inhibiting Akt and NF-kappaB activation. The 
postulated suppression of tumour progression by 
Xanthohumol is based on assays purportedly 
resembling intravasation of tumour emboli through 
defects in the endothelial barrier, so needs much 
further scrutiny. It would be necessary to perform 
in vivo studies, ethically undesirable they might be, 
and ascertain these claims by using stringent criteria 
to evaluate intravasation of tumour cells and 
formation of metastases. 
It may be noted here that Xanthohumol is said to 
inhibit cell motility and EMT activation and this is 
accompanied by inhibition of S100A4 among other 
determinants. Also of interest is that Xanthohumol 
induces apoptosis which is caspase-mediated and 
requires Annexin I. This might be of particular 
interest since S100A4 as well as other S100A 
proteins bind to and regulate the function of many 
target proteins which include annexins. Disruption 
of Annexin/S100A11 alters the phenotypic 
behaviour. Annexins display divergent effects on 
cell proliferation, apoptosis and invasion. The 
effects may relate to whether the specific S100A is 
a tumour promoter or suppressor. It would be 
needless iteration that further investigation is 
warranted. A clinical study of its pharmacokinetics 
has been undertaken (NCT01367431). 
Phenanthrenes are a class of compounds originally 
obtained from various members of Orchidaceae and 
described to possess cytotoxic, antimicrobial and 
anti-inflammatory activity. They may be 
therapeutically important in preventing metastasis 
by inhibiting the interaction of S100A4 with its 
target molecules (see Bresnick AR patent 
WO2011146101 A1).  
The induction of motility response to S100A4 
seems to be mediated by Rho signalling. Rho, Rac 
and Cdc42 are most prominent players in 
cytoskeletal reorganization and modulation of cell 
motility. Of this RhoA has been linked with 
membrane ruffling and cell motility. Recently 
S100A4 has been shown to bind to Rhotekin, a 
RhoA interacting scaffold protein, via the RBD 
(Rho binding domain), but Rho and S1004 seem to 
bind to different residues of RBD. The Rho-
Rhotekin-S100A4 complex generates the invasive 
phenotype. At the practical level it is worthy of note 
and future pursuit that Paclitaxel at low doses well 
below therapeutic levels has been shown to inhibit 
S100A4 in the nuclear compartment and in parallel 
reduce cell migration and invasion in vitro of 
human cholangiocarcinoma cells in a Rho-GTPase 
mediated manner.  
Membrane bound mucins such as MUC16 (CA125) 
and MUC2, MUC4, MUC13 have been associated 
with cancer malignancy. MUC16 is associated with 
the formation of peritoneal metastases in ovarian 
cancer. MUCs 2 and 13 are over expressed in 
pancreatic cancer. MUC4 is overexpressed in 
oesophageal, lung and colon cancer. Its expression 
correlates with progression of pancreatic cancer. 
Experimental suppression of MUC4 in oesophageal 
cancer cells by shRNA reduces S100A4 expression 
and reduces cell proliferation and tumorigenic 
ability as compared with MUC4 expressing parent 
cells.  
The causal linkup is not established; however being 
integral membrane glycoproteins possibly they 
anchor S100A4 to the cell membrane and interferes 
with activation of S100A4 signalling pathways. 
Growth factors are known to induce 
phosphoryalation of the cytoplasmic domain of 
MUC1 and activate nuclear localization of MUC1 
and β-catenin and participate in growth factor 
signalling.  
Little is known about the involvement of the 
immune system in relation to S100A4 function, but 
there are indications that it may be recruited to NK 
cell immune synapses and possibly contribute to 
immune synapse formation. Whether S100A4 
participates in restraining NK lytic function or 
promotes the formation and function of inhibitory 
synapses is uncertain. The cytoplasmic Src kinases 
regulate the activating or inhibitory pathways and it 
has been suggested S100A4 might be capable of 
influencing the operation of these pathways. CTLs 
and NK cells induce apoptosis via the pore forming 
protein perforin and granzyme B pathway. S100A4 
may not be involved in this apoptosis pathway, but 
could be involved in the FasL pathway.  
The non-steroidal anti-inflammatory agent sulindac 
has been found to interfere with Wnt signalling. 
The β-catenin/TCF transcription complex targets 
and regulates S100A4. Using an in vivo model 
involving intrasplenic xenografting of colon cancer 
cells, sulidac has been shown to down regulate 
S100A4 promoter activity and expression together 
with inhibition of Wnt/β-catenin signalling. 
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Phosphosulindac is said to target breast CSCs in 
vitro and induce apoptosis. 
Sulindac is currently being investigated in clinical 
trial on advanced stage IV colorectal cancer 
(NCT01856322). 
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